<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Unlike human hepatic lipase (hHL) that is mainly cell surface-anchored via binding to <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> <z:chebi fb="0" ids="37396">proteoglycans</z:chebi> (HSPG), mouse <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (mHL) has a low affinity to HSPG and thus is largely blood-borne </plain></SENT>
<SENT sid="1" pm="."><plain>The reduced HSPG binding of mHL is attributable to the C-terminal amino acids </plain></SENT>
<SENT sid="2" pm="."><plain>To determine the functions of HSPG binding of hHL in vivo, we created adenovirus vectors encoding hHL or a chimeric protein (designated hHLmt) in which the C-terminal HSPG-binding sequences were replaced with the corresponding mouse sequences </plain></SENT>
<SENT sid="3" pm="."><plain>Injecting hHLmt-expressing virus into C57BL/6J mice (1.8 x 10(10) virus particles/mouse) resulted in a 3-fold increase in pre-<z:chebi fb="5" ids="28304">heparin</z:chebi> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity, whereas <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with an identical dose of hHL virus did not change pre-<z:chebi fb="5" ids="28304">heparin</z:chebi> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity </plain></SENT>
<SENT sid="4" pm="."><plain>In hHLmt-expressing mice, the concentration of total cholesterol and <z:chebi fb="1" ids="16247">phospholipids</z:chebi> was inversely related to the hHL activity in pre-<z:chebi fb="5" ids="28304">heparin</z:chebi> plasma in a dose- and time-dependent manner, and the decrease was mainly attributable to <z:chebi fb="6" ids="39025">high density lipoproteins</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol and <z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The expression of hHL exhibited no change in plasma total cholesterol or <z:chebi fb="0" ids="16247">phospholipid</z:chebi> levels as compared with control mice infected with luciferase or injected with saline </plain></SENT>
<SENT sid="6" pm="."><plain>The reduced <z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="23" ids="18059">lipids</z:chebi> in the hHLmt-expressing mice were accompanied by markedly decreased plasma and hepatic <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) A-I </plain></SENT>
<SENT sid="7" pm="."><plain>In primary hepatocytes isolated from hHLmt-expressing mice, the concentration of cell-associated and secreted apoA-I was decreased by 2-3-fold as compared with hepatocytes isolated from control mice, whereas the levels of apoB and apoE were unaltered </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of primary hepatocytes with hHLmt virus ex vivo also resulted in reduced apoA-I secretion but had no effect on cell-associated apoA-I </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that expression of HSPG binding-deficient hHL has a profound <z:chebi fb="17" ids="39025">HDL</z:chebi>-lowering effect </plain></SENT>
</text></document>